Cytophage Announces Departure of Chief Operating Officer

Winnipeg – April 14, 2026 — Cytophage Technologies Ltd. ("Cytophage" or the "Company") (TSXV: CYTO; FSE: 70G) today announced that the Company's Chief Operating Officer, Ms. Heather Medwick, has left the Company effective March 31, 2026 as a result of the Company's comprehensive corporate restructuring. The corporate restructuring was designed to streamline operations, reduce costs and preserve financial resources of the Company.

"I, and the entire Board of Directors of Cytophage, would like to thank Ms. Medwick for her commitment and dedication throughout her years of service with the Company. Ms. Medwick led the day-to-day operations and administration of Cytophage for the past seven years and played a key role in achieving major milestones for the Company including taking the Company public. We wish her all the best in her new endeavours." said Cytophage Chief Executive Officer and Director, Dr. Steven Theriault.

The Company's Special Committee of independent directors, previously announced on March 6, 2026 continues to evaluate strategic alternatives for the Company including a strategic financing proposal. The Special Committee remains focused on acting in the best interests of all Cytophage shareholders and maximizing value. The Board of Directors has not set a timetable for this process, nor has it made any decisions regarding any potential strategic transaction. There can be no assurance that this process will result in any transaction. The Company does not intend to provide further updates or make further comments regarding these matters unless and until it determines that additional disclosure is appropriate or required by law.

.

About Cytophage

Cytophage Technologies (TSXV:CYTO / FSE: 70G) is a pioneering biotechnology company dedicated to bacteriophage research, product development and commercialization.

Bacteriophages are viruses that only infect and kill bacteria. These natural killers of bacteria can overcome cellular or organism-level defences. They are nature's version of antibiotics.

Cytophage has worked to improve bacteria's natural predators with environmental as well as genetic modifications to bring safe and toxin-free killer solutions to large addressable markets with an initial focus on animal health. and the Company is powered by a large library of phage strains, to address the global challenge of antibiotic resistance ("AMR"). The WHO predicts that AMR will be the leading cause of human mortality by 2050. Many countries have already banned or limited preventative antibiotic use in animal production including 27 EU countries, US, Canada, Brazil, Bangladesh, India and Mexico. In addition to that, consumers all over the world are demanding organic and antibiotic-free products.

For more information on Cytophage Technologies and its innovative work in bacteriophage therapy, please visit www.cytophage.com.

For further information please contact:

Cytophage Technologies Ltd.

James Kinley, Chief Financial Officer: james@cytophage.com

Investor Relations: info@cytophage.com

Cytophage Investor Alerts: https://cytophage.com/subscribe/

Cautionary Statement on Forward-Looking Information

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Cytophage to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in Cytophage’s Filing Statement dated January 30, 2024, which is available for view on SEDAR+ at www.sedarplus.ca. These risks include but are not limited to, the risks associated with the bacteriophage industry, such as operational risks in development or capital expenditures, the uncertainty of extensive regulatory approval requirements, government regulations, protection of intellectual property, product liability and rapid technological advancements. Forward-looking statements contained herein are made as of the date of this press release, and Cytophage disclaims, other than as required by law, any obligation to update any forward-looking statements whether as a result of new information, results, future events, circumstances, or if management’s estimates or opinions should change, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.